AI coach helps doctors explain prostate cancer tradeoffs

NCT ID NCT06856694

Recruiting now Knowledge-focused Sponsor: Cedars-Sinai Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving doctors and patients a report generated by artificial intelligence can improve how well risks and benefits of prostate cancer treatments are discussed. About 283 men with newly diagnosed prostate cancer and their doctors will be randomly assigned to receive either standard educational materials or the AI-generated feedback report after their consultation. The goal is to see if the feedback helps patients feel less conflicted and make choices that better match their values.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NLP+AI-based feedback report
What this could lead to: If successful, this approach could help doctors communicate risks more clearly and support patients in making more informed treatment choices for prostate cancer.
What could go wrong: This is an early-stage study focused on communication, not a direct treatment. The AI feedback may not change patient outcomes or may not work in all settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICALLY LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Communication prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER RISK COMMUNICATION SHARED DECISION MAKING

Contacts and locations

Locations

Cedars Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.